Results 251 to 260 of about 392,840 (300)
Some of the next articles are maybe not open access.
Caffeine and the dopaminergic system
Behavioural Pharmacology, 2005Caffeine is the most widely consumed psychostimulant substance, being self-administered throughout a wide range of conditions and present in numerous dietary products. Due to its widespread use and low abuse potential, caffeine is considered an atypical drug of abuse.
CAULI O, MORELLI, MICAELA
openaire +3 more sources
A dopaminergic mechanism in mania
American Journal of Psychiatry, 1976The authors present a case study that explores the relationship of dopamine function and manic illness through the use of two drugs with relatively specific effects in stimulating and blocking dopamine receptors--piribedil (ET--495) and pimozide, respectively.
Robert H. Gerner +2 more
openaire +2 more sources
Dopaminergic properties of nomifensine
Pharmacology Biochemistry and Behavior, 1982Nomifensine and a proposed dihydroxy metabolite produced stimulation of motor behavior in mice with nomifensine being more potent. Weak cage-climbing behavior (stereotypy) was also produced. The stimulatory effects were greater in mice in which dopamine receptor sensitivity was increased by long-term haloperidol.
Gale Morrow +3 more
openaire +3 more sources
Complications of Dopaminergic Therapy
Disease-a-Month, 2007both of which can be very difficult to manage. 1-3 The delayed use of l-dopa and then when necessary using the minimal amount of l-dopa required to treat symptoms is now an accepted strategy in the management of Parkinson’s disease. This strategy can minimize and/or forestall the development of the troublesome complications of dopaminergic therapy.
Amy Kessler, Michael Rezak
openaire +2 more sources
The dopaminergic system in hypertension
Clinical Science, 2007Dopamine plays an important role in the pathogenesis of hypertension by regulating epithelial sodium transport, vascular smooth muscle contractility and production of reactive oxygen species and by interacting with the renin–angiotensin and sympathetic nervous systems.
Laureano D. Asico +4 more
openaire +3 more sources
Dopaminergic influences on swallowing☆
Neuropharmacology, 1977Abstract Oropharyngeal twitch activity (OTA) exhibited spontaneously in the rat under urethane anaesthesia was compared with swallowing elicited reflexly by electrical stimulation of the superior laryngeal nerve (SLN) or intraoral injection of water. Deglutition was monitored by recording EMGs from muscles of the floor of the mouth, neck and pharynx,
D Bieger, S A Giles, C H Hockman
openaire +3 more sources
Dopaminergic activity of quipazine
Pharmacology Biochemistry and Behavior, 1982Rats were trained to discriminate between the stimulus properties of intraperitoneal 0.16 mg/kg apomorphine and saline in a two-lever, food-motivated operant task. Administration of 1.0 mg/kg quipazine, a putative serotonin agonist, produced apomorphine-appropriate responding with a maximal effect occurring at 45 min post-injection.
Martin D. Schechter, James T. Concannon
openaire +3 more sources
Is there a ?dopaminergic glial cell??
Neurochemical Research, 1984Intracellular cAMP increased 9-fold in cerebral hemisphere primary cultures after incubation with dopamine (10(-4) M). The effect was dose- and time-dependent (10(-6) M-10(-4) M; 2-10 minutes). It was mimicked, to some extent, by the partial agonist apomorphine (10(-5) M-10(-4) M) and antagonized by fluphenazine (10(-5) M-10(-4) M).
Åke Sellström +2 more
openaire +3 more sources
Apomorphine in Dopaminergic Therapy [PDF]
Molecular Pharmaceutics, 2006 Apomorphine is a potent molecule for the treatment of Parkinson's disease (PD). It can be obtained in both the R and S forms, and it is the former that is the therapeutically active form. Due to its structural similarity with 3,4-dihydroxyphenethylamine, dopamine, apomorphine can function as an agonist in the treatment of PD as it can stimulate both ...
openaire +2 more sources
[Continuous dopaminergic stimulation, pulsatile dopaminergic stimulation].
Revue neurologique, 2003Levodopa is the gold standard treatment for Parkinson's disease. The therapeutic effect may however be compromised by the inevitable risk of motor complications, with fluctuating motor control and dyskinesia, particularly in the younger patient. The Multiple pathophysiological mechanisms are undoubtedly involved but pulsed dopaminergic stimulation ...
A., Destée, R., Bordet
openaire +2 more sources